Interview with FAST UK Chairperson Tom Keogh


How was FAST UK born? “FAST (Foundation for Angelman Syndrome Therapeutics) UK was born after our eldest daughter Amelia was diagnosed with Angelman syndrome just after her first birthday. After the initial shock of the diagnosis, my wife Tam and I started looking around to see what help was available and we came across FAST.  […]

August Newsletter

AS & Artificial Intelligence in the News, FAST and Lixte Collaborate to support preclinical study Dr. Jiang seeking participants, Upcoming concert by Joeys Song, IEP Liaison Virginia Spencer accepting applications, An Interview with FAST UK Chairperson Tom Keogh & FAST mask orders Read online

First FAST Gala

1st Gala NewsLetter February2009.2

December 6th 2008 not only marked the official launch of the new foundation, Foundation for Angelman Syndrome Therapeutics(“FAST”), but also became a night to remember and a highlight in the lives of so many parents, families and colleagues touched by an individual with Angelman Syndrome (“AS”). Not only did the event exceed our expectations, but […]

Bienvenue FAST France

Photo FAST France

FAST is proud to announce the newest addition to its global family: FAST France. Charlotte Prestat and Anthony Moisan, the founders of FAST France, have three children. After receiving a diagnosis of Angelman syndrome in 2017 for their middle daughter Héloïse, the two science-minded engineers researched as much as they could on the syndrome. Their […]

Global Angelman Syndrome Registry moves platform to QUT


The Global Angelman Syndrome Registry (Registry) had some downtime this week while the platform was moved to the Division of Research and Innovation at QUT (Queensland University of Technology). The move will mean there is a much larger team allowing new functions and materials available more quickly, making the  Registry more user friendly for over 1,400 participants in 65 countries and providing new users with […]

Frequently asked questions regarding the GeneTx KIK-AS Clinical Trial

blog faq

GeneTx Biotherapeutics has announced it has received IRB approval from Rush University Medical Center in Chicago, IL to begin the “KIK-AS” (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) Phase 1/2 clinical study of GTX-102. What does this mean? The United States Food and Drug Administration’s Investigational New Drug (IND) program is the means by […]

A message to the Angelman community from GeneTx Biotherapeutics

Two press releases were issued recently with one announcing an Exclusive Option Agreement between GeneTx Biotherapeutics, LLC (“GeneTx”) and  Ultragenyx Pharmaceutical, Inc. (“Ultragenyx”), and the other announcing GeneTx’s lead candidate receiving Orphan Drug Designation (ODD) and Rare Pediatric Drug Designation (RPD). GeneTx would like to take this opportunity to provide additional information to our community about this […]

GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment

Downers Grove, Ill., March 27, 2018 – The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of Angelman syndrome, a rare neurogenetic disorder that affects approximately one in 15,000 people. GTX-101 is the first drug candidate for the startup biotechnology company. “No approved treatments for Angelman […]

New biotech launched for antisense program targeting Angelman syndrome

Downers Grove, Ill., Feb. 22, 2018 – FAST (Foundation for Angelman Syndrome Therapeutics) announced today the launch of GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for the development and commercialization of an investigational antisense drug, GTX-101, for the treatment of Angelman syndrome (AS). FAST selected Paula Evans, the chairperson of FAST, to serve as […]

About GeneTx

Beginning in early 2012, FAST began funding the Dindot laboratory at Texas A&M University to understand the mechanism by which UBE3A-AS turns off the paternal UBE3A allele, why the paternal UBE3A allele is off in neurons, and how that process may be circumvented as a potential therapy for AS. Research in the Dindot laboratory identified […]